Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS. - Wikidata - awgldk - TriplyDB

Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS.

Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS.

http://www.wikidata.org/entity/Q34684038

about

Therapeutics for Graft-versus-Host Disease: From Conventional Therapies to Novel Virotherapeutic Strategies Modern approaches to HLA-haploidentical blood or marrow transplantation Effects of T-Cell Depletion on Allogeneic Hematopoietic Stem Cell Transplantation Outcomes in AML Patients The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease Alternative Donor Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis Hematopoietic stem cell transplantation for homozygous β-thalassemia and β-thalassemia/hemoglobin E patients from haploidentical donors.Outcomes of acute leukemia patients transplanted with naive T cell-depleted stem cell grafts.Single-Agent Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis after Human Leukocyte Antigen-Matched Related Bone Marrow Transplantation for Pediatric and Young Adult Patients with Hematologic Malignancies.Therapeutic drug monitoring for either oral or intravenous busulfan when combined with pre- and post-transplantation cyclophosphamide.OCTET-CY: a phase II study to investigate the efficacy of post-transplant cyclophosphamide as sole graft-versus-host prophylaxis after allogeneic peripheral blood stem cell transplantation Pediatric chronic myeloid leukemia is a unique disease that requires a different approach Anti-thymocyte globulin as graft-versus-host disease prevention in the setting of allogeneic peripheral blood stem cell transplantation: a review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide.Plasma-derived proteomic biomarkers in human leukocyte antigen-haploidentical or human leukocyte antigen-matched bone marrow transplantation using post-transplantation cyclophosphamide.Stem cell transplantation for the treatment of immunodeficiency in children: current status and hopes for the future.Tregs: hype or hope for allogeneic hematopoietic stem cell transplantation?Ex vivo T-cell depletion in allogeneic hematopoietic stem cell transplant: past, present and future.Role of the Immune Response in Disease Progression and Therapy in Multiple Myeloma.Primary Immune Deficiency Treatment Consortium (PIDTC) update.Efficacy of antithymocyte globulin for allogeneic hematopoietic cell transplantation: a systematic review and meta-analysis.Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide.Post-transplant cyclophosphamide, a promising anti-graft versus host disease prophylaxis: where do we stand?Autologous stem cell transplantation is still a valid option in good- and intermediate-risk AML: a GITMO survey on 809 patients autografted in first complete remission.Haploidentical Related Donor Hematopoietic Stem Cell Transplantation for Dedicator-of-Cytokinesis 8 Deficiency Using Post-Transplantation Cyclophosphamide.High-dose Cyclophosphamide is Effective Therapy for Pediatric Severe Aplastic Anemia.Adenosine Selectively Depletes Alloreactive T Cells to Prevent GVHD While Conserving Immunity to Viruses and Leukemia.Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide in a Patient with Chronic Granulomatous Disease and Active Infection: A First Report.T-replete haploidentical allogeneic transplantation using post-transplantation cyclophosphamide in advanced AML and myelodysplastic syndromes.Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation.Early tapering of immunosuppressive agents after HLA-matched donor transplantation can improve the survival of patients with advanced acute myeloid leukemia.Neutrophils provide cellular communication between ileum and mesenteric lymph nodes at graft-versus-host disease onset.Post-Transplantation Cyclophosphamide after Bone Marrow Transplantation Is Not Associated with an Increased Risk of Donor-Derived Malignancy.Role of αβ T Cell Depletion in Prevention of Graft versus Host Disease.Targeting Aurora kinase A and JAK2 prevents GVHD while maintaining Treg and antitumor CTL function.Stability of Chimerism in Non-Obese Diabetic Mice Achieved By Rapid T Cell Depletion Is Associated With High Levels of Donor Cells Very Early After Transplant.Mismatched unrelated hematopoietic stem cell transplantation with post-transplant cyclophosphamide for high-risk acute myeloid leukemia.Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis in HLA matched sibling or matched unrelated donor transplant for patients with acute leukemia, on behalf of ALWP-EBMT.

P2860

Q26751959-27B3E4C6-1304-4E18-917D-31FD3E261CF4 Q26797506-D1D027FD-3D15-4AFF-A25D-9DDF159A3F77 Q26799602-722C883A-4398-4E38-80E8-B2B0DE2A89E9 Q28076264-831381EE-F9B3-401F-B944-5B825FBBE6EB Q28080943-5FCBB033-7C8B-47E0-B241-AE713EDABB8B Q33815986-E6F013BC-40BE-421D-96D5-1AD183F6BCCC Q35924098-5804EDF3-2594-4B57-8AAE-D23F25290822 Q36040293-1867A4E7-AD80-4756-AB77-7836271FA856 Q36445665-4CAD48B3-7529-462C-8FF4-D1C1F5EFE5E7 Q36703516-205D2053-7A1A-450B-9D84-C280BC5183F5 Q36833808-8B86B35D-D225-4CF0-8893-3638EB912361 Q37025981-B1A5F13F-04B4-440F-AC70-3458F6C20FFE Q37618811-6FC26FEA-6670-45D0-A6A3-90E1A6C4B558 Q37618838-DD0A40AF-1A94-4549-8605-B92756FF803B Q38381708-D35D4A94-89AD-47A2-BD3E-53B1EC28E7DD Q38735833-C47FAAFD-F1AD-47D4-AA5B-3682DC449DB5 Q38742863-1C597430-8E8E-4CF9-B05C-A3E18853DD2C Q38742867-31EBFC19-535F-4085-88AE-4F13CDD5E50A Q38815399-5465FCCE-FF3A-4AEA-A068-7FEEA56C2BC0 Q38855061-59DBF397-6FBF-4AFC-B2A8-84011CDA2430 Q39036486-E6C86EA4-4B40-4DA5-AB44-A2DE45CD7D0B Q39042251-E0969EE2-F4C2-4A65-A532-0673537132D3 Q39232385-291205A1-ACCB-49B4-82A0-174B015FF823 Q39351385-832469E3-F18E-4D77-ABEA-53FF78FBC29B Q40296052-637BFE70-6220-475F-947F-51134BFC1114 Q40496183-FFD8A6F7-5615-4DFF-A195-F1FADE0F9062 Q40657274-BB638977-4170-4AE0-A0BB-82628B671242 Q40959068-D14DCE25-F95D-4DA3-9CD1-06515A432EC8 Q41138074-5235F662-F086-4822-93FB-11A6CF25B5E5 Q43272332-0BB2D27D-3C0D-4BE5-A67A-A40ACE78C431 Q48103108-4F5F2297-F582-42A4-9DF4-9820665EFBBD Q49791828-7060384E-8E34-4716-AF06-C97D43D1D8B6 Q50966214-D12FF2AE-1337-4D7D-A88A-BE213D26FB00 Q52763837-C080D527-A91A-4C75-8E2E-0DFF9EA7D893 Q52927960-24EF2DE2-8569-4482-A52F-D9DF1619ECEE Q53824120-4CAF11DB-4D74-4EE0-809C-CE5763AC8EA0 Q53979038-F6803E1B-28F0-414F-A619-B0A9F2226F1A Q55240175-25240E48-D5F4-4D74-818F-725616FE1B51

P2860

Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS.

http://www.wikidata.org/entity/Q34684038

description

2014 nî lūn-bûn

@nan

2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Single-agent GVHD prophylaxis ...... hed BMT for AML, ALL, and MDS.

@ast

Single-agent GVHD prophylaxis ...... hed BMT for AML, ALL, and MDS.

@en

Single-agent GVHD prophylaxis ...... hed BMT for AML, ALL, and MDS.

@nl

type

label

Single-agent GVHD prophylaxis ...... hed BMT for AML, ALL, and MDS.

@ast

Single-agent GVHD prophylaxis ...... hed BMT for AML, ALL, and MDS.

@en

Single-agent GVHD prophylaxis ...... hed BMT for AML, ALL, and MDS.

@nl

prefLabel

Single-agent GVHD prophylaxis ...... hed BMT for AML, ALL, and MDS.

@ast

Single-agent GVHD prophylaxis ...... hed BMT for AML, ALL, and MDS.

@en

Single-agent GVHD prophylaxis ...... hed BMT for AML, ALL, and MDS.

@nl

P1433

Q34684038-8EBBC39E-DB98-46CE-AA11-A14CBDC1834E

P1476

Q34684038-F47DCC4F-A46D-4F95-887A-10369B782888

P2093

Q34684038-0DF611B7-8FBC-44D1-B643-83C616CED7AD

Q34684038-1747C4C2-414A-4AFE-AA73-E3D5F39A26D2

Q34684038-1D2B55E2-C9FB-4923-A00D-3BDC6DD3E399

Q34684038-20854364-0FB6-4DBC-B791-6AD380CBA8C3

Q34684038-40E3AB44-0A4C-4390-9D68-8342A38B7C82

Q34684038-5E3A5400-96A7-41FB-B04A-7D45920DDB69

Q34684038-64A7D112-2398-47BF-B4EF-1F8C3A782D7D

Q34684038-6727D3C4-A059-4728-9C82-975C80C4462B

Q34684038-68E7F0C1-B1E9-4010-A0A7-660F08747C12

Q34684038-7AC199BF-2E1E-4933-954C-89EE5EF6CE1A

P2860

Q34684038-0656106C-8682-4F2C-81DC-CA03205030D4

Q34684038-0AF36B7D-5375-45DD-8CFC-6969A953510E

Q34684038-10A22856-9BDD-4CC4-B5CF-C71DE56F0C4C

Q34684038-1752B216-86D8-463A-BBC4-2CAE84204043

Q34684038-20BA5AC7-E52D-4498-AECA-64369F993729

Q34684038-2CD96558-FC5E-4D42-943D-CA8EA687D680

Q34684038-31E92D56-BA79-48E0-8486-EB5A8DF56D0A

Q34684038-33966399-9E98-413B-950D-F60D0AB6D303

Q34684038-3EBC9D22-AD17-43EF-AB3F-6E47F121A16F

Q34684038-3FE49B6A-3E8B-4C55-8EEA-CAD6C36B5900

P304

Q34684038-42E30A7D-FAFE-4D12-9D93-4EF55C1738D1

P31

Q34684038-7DD001A7-6F07-4483-89A3-4C282067679D

P356

Q34684038-1DABC4B2-0F99-4E73-A4E4-052EF8562F02

P407

Q34684038-9DB23CCF-84A1-47C8-A4A6-C0E1803CB9F7

P433

Q34684038-9D981D54-022A-4D04-9B4C-6573F59B1156

P478

Q34684038-67DD16A7-85CA-42E1-A7FB-8C59BEC7666D

P577

Q34684038-71B02615-15C4-4CED-811B-814EC3AA30FC

P5875

Q34684038-47B45E96-C517-4733-A90A-920B44821059

P698

Q34684038-F0454EDC-7ACE-42A7-83FA-A4A3397F06F4

P932

Q34684038-C75C9472-72F9-4316-BDD3-7B6C3047FB8B

P356

BLOOD-2014-07-587477

P1433

P1476

Single-agent GVHD prophylaxis ...... hed BMT for AML, ALL, and MDS.

@en

P2093

Amy E DeZern

http://www.w3.org/2001/XMLSchema#string

B Douglas Smith

http://www.w3.org/2001/XMLSchema#string

Carol Ann Huff

http://www.w3.org/2001/XMLSchema#string

Christopher G Kanakry

http://www.w3.org/2001/XMLSchema#string

Douglas E Gladstone

http://www.w3.org/2001/XMLSchema#string

Ephraim J Fuchs

http://www.w3.org/2001/XMLSchema#string

Gary L Rosner

http://www.w3.org/2001/XMLSchema#string

Hua-Ling Tsai

http://www.w3.org/2001/XMLSchema#string

Ivan Borrello

http://www.w3.org/2001/XMLSchema#string

Ivana Gojo

http://www.w3.org/2001/XMLSchema#string

P2860

Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT

Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation

Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study

International scoring system for evaluating prognosis in myelodysplastic syndromes

Ex vivo T cell-depleted versus unmodified allografts in patients with acute myeloid leukemia in first complete remission.

High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease.

High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation

Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide

Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning

Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multi-centre, randomised phase II-III trial.

P304

3817-3827

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2014-07-587477

http://www.w3.org/2001/XMLSchema#string

P407

P433

25

http://www.w3.org/2001/XMLSchema#string

P478

124

http://www.w3.org/2001/XMLSchema#string

P577

2014-10-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

266946151

http://www.w3.org/2001/XMLSchema#string

P698

25316679

http://www.w3.org/2001/XMLSchema#string

P932

4263989

http://www.w3.org/2001/XMLSchema#string